Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561897 | PMC |
http://dx.doi.org/10.3389/fpsyg.2022.1020222 | DOI Listing |
J Am Acad Child Adolesc Psychiatry
December 2024
UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, California; The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles, California.
We are writing in response to 2 Letters to the Editor, both of which discussed our commentary, entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution." We appreciate the thoughtful responses to our commentary, and we invite further dialogue about this important subject. Both letters emphasized the importance in engaging in thoughtful research approaches to ensure the safety of individuals who are administered psychedelics.
View Article and Find Full Text PDFJ Am Acad Child Adolesc Psychiatry
December 2024
Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution." We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine.
View Article and Find Full Text PDFJ Am Acad Child Adolesc Psychiatry
December 2024
Massachusetts General Hospital, Boston, Massachusetts.
We read with interest the Commentary by Jeffrey et al. encouraging clinical research using psychedelics for adolescents. Throughout their commentary, the authors operate under the general presupposition that psychedelics have demonstrated a favorable safety profile in adults, and that therefore teenagers approaching an adult level of neurodevelopment can likely be safely treated with appropriate safeguards.
View Article and Find Full Text PDFJ Am Acad Psychiatry Law
December 2024
Dr. Schonholz is a psychiatry resident, Mount Sinai Hospital, New York, NY. Dr. Appel is a Professor of Psychiatry and Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Bursztajn is an Associate Professor of Psychiatry and cofounder, Program in Psychiatry and the Law, Beth Israel Deaconess Medical Center Psychiatry, Harvard Medical School, Boston, MA and President, American Unit of the International Chair in Bioethics, Cambridge, MA. Dr. Nair is in private practice, Clinical & Forensic Neuropsychiatry/Brain Injury Medicine, Seal Beach, CA. Dr. MacIntyre is a Health Sciences Clinical Assistant Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Preliminary research shows the psychedelic psilocybin to be a promising potential treatment for psychiatric illnesses. Recent U.S.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!